Normosang (Human Hemin)

• Normosang is used in the management of acute hepatic porphyria, targeting the heme biosynthetic pathway to control attacks.
• Acute intermittent porphyria: reduces the severity and duration of acute attacks by supplying heme.
• Acute hepatic porphyria (non‑intermittent): helps terminate an ongoing porphyria crisis through ALAS down‑regulation.
• Porphyria‑induced neurovisceral symptoms: alleviates abdominal pain, nausea and neurological manifestations during an attack.

• Human Hemin acts as an exogenous source of heme, which provides negative feedback to the rate‑limiting enzyme aminolevulinic acid synthase (ALAS) in the hepatic mitochondria. By suppressing ALAS activity, the drug decreases the production of aminolevulinic acid and porphobilinogen, the toxic precursors that accumulate during acute porphyria attacks. This restoration of heme balance reduces neurovisceral symptoms and prevents further buildup of harmful porphyrin intermediates.

Human Hemin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Infusion site pain: discomfort or burning at the injection site.
• Nausea: feeling of sickness often occurring during or after infusion.
• Vomiting: expulsion of stomach contents following treatment.
• Headache: mild to moderate head pain during therapy.
• Fever: transient rise in body temperature post‑infusion.
• Hypotension: temporary drop in blood pressure during administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Hemolysis: destruction of red blood cells leading to anemia.
• Hepatic injury: elevation of liver enzymes indicating liver stress.
• Coagulopathy: abnormal bleeding or clotting disorders.
• Renal failure: acute kidney injury associated with high‑dose therapy.
• Thrombosis: formation of blood clots in veins or arteries.

When using Normosang, several precautionary measures should be observed to ensure patient safety.

• Monitor liver function: assess hepatic enzymes before and during therapy.
• Assess renal function: evaluate kidney parameters, especially in patients with pre‑existing impairment.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Caution with iron overload: patients with high iron stores require careful evaluation.
• Observe for infusion reactions: use slow infusion rates and monitor vital signs.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin can interact with other medicines, influencing their efficacy or safety.

Major Interactions (Avoid)

• Barbiturates (e.g., phenobarbital): potent inducers of ALAS that may counteract hemin therapy.
• Sulfonamide antibiotics: porphyrinogenic agents that can exacerbate porphyria.
• Hormonal contraceptives containing estrogen: may increase porphyrin synthesis and reduce treatment effectiveness.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): hemin may affect coagulation parameters, requiring INR monitoring.
• Antihypertensive agents: risk of additive hypotensive effect during infusion.
• Other intravenous solutions: incompatibility with certain electrolytes; verify compatibility before mixing.